Clinical trials: Epithelial Cancer, open to volunteers
Epithelial Ovarian Cancer, Ovarian Neoplasms
Centralization and Oncologic Outcomes in Ovarian Cancer
This is a multicenter, observational, retrospective and prospective study conducted within the REMO (Reggio Emilia - Modena) network in the Emilia-Romagna region (Italy), promoted by AUSL-IRCCS of Reggio Emilia.
- Conditions
- Epithelial Ovarian Cancer, Ovarian Neoplasms, Advanced Ovarian Cancer
- Trial name
- COOC - REMO (NCT07075939)
- Testing
- No Intervention: Observational Cohort
- Where
- 7 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Oropharynx Cancer
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
This is a trial studying patients with human papilloma virus (HPV) positive oropharyngeal cancer with tumors that can be removed via transoral surgery.
- Trial name
- NCT05388773
- Testing
- therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Heath Skinner
Epithelial Ovarian Cancer
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or…
- Trial name
- TREVI-OC-01 (NCT07218809)
- Testing
- AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel
- Where
- 299 sites in United States, Australia and 22 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca
Thymus Neoplasms, Thymic Epithelial Tumor
Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors
This is a multi-center, open-label, single-arm, prospective interventional study evaluating hypofractionated adjuvant radiotherapy (HART) after radical thymothymectomy in patients with thymic epithelial tumors.
- Conditions
- Thymus Neoplasms, Thymic Epithelial Tumor, Thymoma, Thymic Carcinoma
- Trial name
- THOR (NCT07693855)
- Testing
- Hypofractionated Adjuvant Proton Therapy, Hypofractionated Adjuvant Photon Radiation Therapy
- Where
- 3 sites in Taiwan
- Volunteers
- 69 people
- Sponsor
- National Taiwan University Hospital
Thymic Epithelial Tumor
Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors
This is a prospective, open-label, single-arm Phase II study designed to evaluate the safety of postoperative hypofractionated radiotherapy in patients with Stage II/III thymic epithelial tumors after complete resection.
- Trial name
- TET-HFRT40 (NCT07691619)
- Testing
- Postoperative hypo-fractionated radiotherapy
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT06994195
- Testing
- BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer, Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer
A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting
Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancers, is a lethal disease with 3,221 new cases reported in 2021 in Korea.
- Conditions
- Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer, Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer, Folate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer
- Trial name
- NCT07687602
- Volunteers
- 69 people
- Sponsor
- AbbVie
Ovarian Cancer, Ovarian Carcinoma
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training/MBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary…
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Stage II Ovary Cancer, Stage II Ovarian Cancer
- Trial name
- NCT05429970
- Testing
- Mind-body resilience training, Music therapy, Propranolol
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Epithelial Ovarian Cancer, Fallopian Tube Cancers
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
To observe the efficacy and safety of IMMU-132 in patients with advanced or recurrent ovarian cancer with high TROP-2 expression in tumor tissue, who have failed standard therapy or are unable to receive standard treatment.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary, Primary Peritoneal Carcinoma
- Trial name
- NCT07674615
- Testing
- Sacituzumab govitecan monotherapy
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-expressing platinum-resistant recurrent epithelial ovarian cancer…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07545460
- Testing
- BL-M07D1, Liposomal Doxorubicin, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 404 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Ovarian Neoplasms, Carcinoma, Ovarian Epithelial
Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy
The purpose of this observational study is to learn if a specialized blood test can help predict whether advanced ovarian cancer will return after a patient's initial treatments are finished.
- Conditions
- Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Ovarian Cancer
- Trial name
- NCT07670962
- Testing
- Blood-based ctDNA minimal residual disease (MRD) test
- Volunteers
- 300 people
- Sponsor
- Asan Medical Center
Pancreatic Ductal Carcinoma, Advanced Cancer
Using Tumor Models to Determine Treatments
The purpose of this study is to see if using Patient Derived Organoids (PDO) to choose a drug for the treatment of pancreatic cancer individually for each patient is useful.
- Conditions
- Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial Tumor
- Trial name
- NCT06813079
- Testing
- Cobimetinib, Ponatinib, Brigatinib
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- University Health Network, Toronto
Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
This phase II trial studies the side effects of ONC201 and paclitaxel and how well they work in treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back…
- Conditions
- Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
- Trial name
- NCT04055649
- Testing
- Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Ira Winer
Epithelial Cancer Patients
Phase I/IIa Clinical Trial of IMC001 in Patients With Advanced Epithelial Solid Tumors.
This is an open -label phase I /IIa study designed to evaluate the safety and efficacy of IMC001 in patients with advanced epithelial solid tumors.
- Trial name
- IMC001 EpCAM (NCT07644403)
- Testing
- Autologous CAR-T cell injection targeting EpCAM
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Suzhou Immunofoco Biotechnology Co., Ltd
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
- Trial name
- DUAL-OV-CAR-NK (NCT07617753)
- Testing
- Dual-target CAR-NK cell product, Cyclophosphamide, supportive
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of for Mirvetuximab Soravtansine in participants with…
- Conditions
- Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
- Trial name
- NCT06682988
- Testing
- Mirvetuximab Soravtansine
- Where
- 52 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- AbbVie
HER2-Expressing Solid Tumors
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
This clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-304 in adults with advanced HER2-expressing solid tumors.
- Trial name
- NCT07334119
- Testing
- MT-304, MT-304 + Nivolumab
- Where
- 7 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Myeloid Therapeutics
B2 Thymoma, Thymic Carcinoma
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma.
- Trial name
- SELECT-NK-THYM (NCT07598955)
- Testing
- Cyclophosphamide, Fludarabine, EB-CAR30-NK
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Ovary Neoplasm, Ovarian Cancer
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian…
- Conditions
- Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent
- Trial name
- NCT06305299
- Testing
- iC9-CAR.B7-H3 T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of liposomal irinotecan combined with enlonstobart in patients with platinum-resistant recurrent ovarian…
- Conditions
- Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers, Epithelial Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07591831
- Testing
- Liposomal Irinotecan
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital